Skip to main content
OpenTrials
Completed

NCT Number: NCT03210558

Study of Testosterone and Athlete Response

Trial objectives and purpose: The primary aim is to study the effects of moderately increased testosterone concentration on aerobic performance (endurance running time to exhaustion), and secondary aims to investigate the effects on submaximal work on treadmill, anaerobic capacity, muscle strength, body composition, behaviour and well-being, blood parameters, steroid hormone profile, gynecological parameters and skeletal muscle parameters in young healthy women in a double-blind, randomized, placebo-controlled trial.

Treatment: Ten weeks of transdermal treatment with testosterone cream 10 mg daily or placebo cream in a randomized design (1:1).

Primary outcome: Aerobic performance (running time to exhaustion on treadmill)

Secondary outcomes:

1. Submaximal work on treadmill (oxygen uptake, ventilation, heart rate, blood lactate and subjective rate of exhaustion) 2. Anaerobic performance (Wingate test) 3. Muscle strength (Cybex apparatus, force transducer, counter movement jump) 4. Body composition (Dual X-ray Absorptiometry: muscle mass, fat mass, bone mass) 5. Behaviour and well-being (Quality of life, Profile of mood state, Confidence Questionnaire, Aggression Questionnaire) 6. Blood parameters (hemoglobin, hematocrit, reticulocytes, ferritin, CRP) 7. Steroid hormone profile in blood and urine 8. Gynecological evaluation (ovarian and endometrial variables on ultrasound) 9. Skeletal muscle morphology, metabolic enzymes and muscle protein synthesis

Study population: Fifty healthy menstruating women will be included in the study and randomized to treatment with testosterone or placebo. Inclusion criteria: 18-35 yrs of age; body mass index (BMI) 19-25; non-smoking; a moderate to high self-reported level of recreational physical activity; not taking hormonal contraception and willing to use highly efficient non-hormonal contraception during the study (intrauterine device, bilateral tubal occlusion, vasectomised partner, same-sex partner, or sexual abstinence); accepting to not participate in any sports competitive event during the study period plus one month. Exclusion criteria: the presence of cardiovascular, liver, biliary or renal disease; hyperlipidemia; uncontrolled high blood pressure; endocrinological disorder; oligomenorrhea (menstrual intervals of more than 6 weeks) or amenorrhea (no menstruation for at least 3 months); pregnancy; a history of thromboembolic disorder; any malignancy; and intake of hormonal contraception the last two months prior to the study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Department of Obstetrics and Gynecology, Karolinska University Hospital

Stockholm, 171 76, Sweden

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

are: healthy menstruating women; 18-35 yrs of age; BMI 19-25; non-smoking; having a moderate to high self-reported level of recreational physical activity (minimum of three hours of endurance and/or strength training per week); not taking hormonal contraception; and willing to use highly efficient non-hormonal contraception during the study such as:

  • Intrauterine device
  • Bilateral tubal occlusion
  • Vasectomised partner
  • Same-sex partner
  • Sexual abstinence

Exclusion criteria

are: the presence of cardiovascular, liver, biliary or renal disease; hyperlipidemia; uncontrolled high blood pressure; endocrinological disorder; oligomenorrhea (menstrual intervals of more than 6 weeks) or amenorrhea (no menstruation for at least 3 months); pregnancy; a history of thromboembolic disorder; any malignancy; and intake of hormonal contraception the last two months prior to the study.

Treatment and study plan

Testosterone cream 1% (Andro-Feme® )

Drug

Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.

placebo cream

Drug

Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.

Primary outcomes

  1. Aerobic performance

    Time frame: Baseline and 10 weeks of treatment

    Change in endurance exercise time to exhaustion on treadmill

Secondary outcomes

  1. Submaximal work on treadmill

    Time frame: Baseline and 10 weeks of treatment

    Change in oxygen uptake (L/min, mL/kg x min)

  2. Anaerobic performance (Wingate test)

    Time frame: Baseline and 10 weeks of treatment

    Change in average power output on a cycle ergometer (W)

  3. Muscle strength (knee extension torque)

    Time frame: Baseline and 10 weeks of treatment

    Change in peak muscle strength (N) and strength endurance (time)

  4. Functional power development-jump tests

    Time frame: Baseline and 10 weeks of treatment

    Change in jump height (m) by squat jump and countermovement jump

  5. Physical activity during one week before treatment and one week before the end of treatment

    Time frame: Baseline and 10 weeks of treatment

    Change in accelerometer counts

  6. Muscle mass

    Time frame: Baseline and 10 weeks of treatment

    Change in muscle mass (g) by DXA

  7. Body fat percentage

    Time frame: Baseline and 10 weeks of treatment

    Change in body fat (%) by DXA

  8. Bone mineral density

    Time frame: Baseline and 10 weeks of treatment

    Change in bone mineral density (g/cm2) by DXA

  9. Psychological General Well-Being

    Time frame: Baseline and 10 weeks of treatment

    Change in Psychological General Well-Being (PGWB) score 0 (poor quality of life) and 110 (good quality of life)

  10. Mood

    Time frame: Baseline and 10 weeks of treatment

    Change in mood (POMS) score 0 (not at all) to 4 (very much)

  11. Confidence

    Time frame: Baseline and 10 weeks of treatment

    Change in confidence (Confidence Questionnaire) score 1 (not at all) to 5 (very much)

  12. Aggression

    Time frame: Baseline and 10 weeks of treatment

    Change in aggression (Aggression Questionnaire) score 1 (does not fit in with me at all) to 5 (totally fits in with me)

  13. Blood parameters

    Time frame: Baseline and 10 weeks of treatment

    Change in blood parameters (hemoglobin, hematocrit, reticulocytes, ferritin, CRP)

  14. Steroid hormone profile in blood and urine

    Time frame: Baseline and 10 weeks of treatment

    Change in steroid hormones and metabolites in blood (testosterone, dihydrotestosterone, androstenedione, estradiol, dehydroepiandrosterone and its sulfate, cortisol, progesterone, other reproductive hormones (LH, FSH, AMH), binding protein (SHBG) and steroid hormones and metabolites in urine (estrone, estrone sulfate, androsterone glucuronide, 5α androstane-3α, 17β-diol 17-glucuronide, androst-5-ene-diol-3β, 17β-diol, testosterone, androstenedione, epitestosterone, androsterone, etiocholanolone).

  15. Gynecological evaluation

    Time frame: Baseline and 10 weeks of treatment

    Change in ultrasound assessments of the endometrium (mm) and ovaries (volume)

  16. Skeletal muscle

    Time frame: Baseline and 10 weeks of treatment

    Change in morphology and concentration of metabolic enzymes (HAD, SC), markers of muscle protein synthesis (mTOR, p70), as well as markers from the muscle atrophy pathway (MABbx, MuRF-1)

Sponsors and collaborators

Lead sponsor

Karolinska University Hospital

Other

Collaborators

  • The Swedish School of Sport and Health Sciences

Registry information

Official study title

Effects of Moderately Increased Testosterone Concentration on Physical Performance and Behaviour in Healthy Women - a Double-blind, Randomized, Placebo-controlled Study

Acronym: STAR

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jul 7, 2017
Registry last updated
Oct 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.